<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03629015</url>
  </required_header>
  <id_info>
    <org_study_id>AA01</org_study_id>
    <nct_id>NCT03629015</nct_id>
  </id_info>
  <brief_title>Safety Study of Stemchymal® in Acute Liver Failure</brief_title>
  <acronym>ALF</acronym>
  <official_title>The Safety Study of Stemchymal® (Allogeneic Adipose-Derived Mesenchymal Stem Cells) Treating on Acute Liver Failure - An Open-Label, Single-Center Phase I Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Steminent Biotherapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Taipei Veterans General Hospital, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Steminent Biotherapeutics Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the safety of Stemchymal® via intravenous (IV) infusion in acute liver failure
      (ALF) and acute on chronic liver failure (ACLF) patients.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2018</start_date>
  <completion_date type="Anticipated">October 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 29, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of adverse events (AEs) and suspected unexpected serious adverse reaction (SUSAR)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Changes of Model for End-Stage Liver Disease score</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes of Child-Pugh score</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes of Eastern Cooperative Oncology Group performance scale</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Stem Cells</condition>
  <condition>Adult Stem Cells</condition>
  <condition>Acute Liver Failure</condition>
  <condition>Acute-On-Chronic Liver Failure</condition>
  <condition>Steminent</condition>
  <arm_group>
    <arm_group_label>Stemchymal®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biological: Stemchymal® ALF/ ACLF patients will receive low (0.5 x 10^6 cells/kg) or high (2 x 10^6 cells/kg) dose of Stemchymal® through intravenous infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Stemchymal®</intervention_name>
    <description>ALF/ ACLF patients will receive Stemchymal® through intravenous infusion</description>
    <arm_group_label>Stemchymal®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ALF or ACLF patients.

          2. Subjects are between 20 and 70 years of age.

          3. MELD scores meet 17 ≤ MELD ≤ 26.

          4. Subjects who had completed signing informed consent.

        Exclusion Criteria:

          1. Subjects who had been enrolled in any other cell therapy within six months.

          2. Females with a positive pregnancy test result.

          3. Subjects have contraindication for liver transplantation.

          4. Subjects with psychiatric illnesses.

          5. Subjects who are diagnosed as active tuberculosis (TB).

          6. Subjects with immunological disorders (e.g. autoimmune hepatitis) or using
             immunosuppressive drugs (e.g. steroid for immunosuppression) within six months prior
             to screening visit.

          7. Subjects with unstable illnesses or contraindication for this clinical trial according
             to investigator's judgment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chih-Yuan Ho, PhD</last_name>
    <phone>+886-2-26279216</phone>
    <phone_ext>670</phone_ext>
    <email>kevinho@steminent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>July 30, 2018</study_first_submitted>
  <study_first_submitted_qc>August 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2018</study_first_posted>
  <last_update_submitted>August 9, 2018</last_update_submitted>
  <last_update_submitted_qc>August 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Hepatic Insufficiency</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
    <mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
    <mesh_term>Liver Failure, Acute</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

